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Abstract
Background: The first changes associated with smoking are in the small airway epithelium (SAE). Given that smoking alters
SAE gene expression, but only a fraction of smokers develop chronic obstructive pulmonary disease (COPD), we
hypothesized that assessment of SAE genome-wide gene expression would permit biologic phenotyping of the smoking
response, and that a subset of healthy smokers would have a ‘‘COPD-like’’ SAE transcriptome.
Methodology/Principal Findings: SAE (10th–12th generation) was obtained via bronchoscopy of healthy nonsmokers,
healthy smokers and COPD smokers and microarray analysis was used to identify differentially expressed genes. Individual
responsiveness to smoking was quantified with an index representing the % of smoking-responsive genes abnormally
expressed (ISAE), with healthy smokers grouped into ‘‘high’’ and ‘‘low’’ responders based on the proportion of smoking-
responsive genes up- or down-regulated in each smoker. Smokers demonstrated significant variability in SAE transcriptome
with ISAE ranging from 2.9 to 51.5%. While the SAE transcriptome of ‘‘low’’ responder healthy smokers differed from both
‘‘high’’ responders and smokers with COPD, the transcriptome of the ‘‘high’’ responder healthy smokers was
indistinguishable from COPD smokers.
Conclusion/Significance: The SAE transcriptome can be used to classify clinically healthy smokers into subgroups with
lesser and greater responses to cigarette smoking, even though these subgroups are indistinguishable by clinical criteria.
This identifies a group of smokers with a ‘‘COPD-like’’ SAE transcriptome.
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Introduction
Cigarette smoke, composed of .10
3 xenobiotics and 10
14 free
radicals per puff, places a significant stress on the lung [1–4]. A
particularly vulnerable cell population is the airway epithelium, the
endoderm-derived, pseudostratified layer of cells lining the
tracheobronchial tree [5,6]. The airway epithelium is the first line
of defense against cigarette smoke, and it is the epithelium of the
small airways (,2 mm diameter, $6 generations) that shows the
first morphologic changes in smokers [7–10]. With continued
smoking, 15 to 20% of smokers progress and develop chronic
obstructive pulmonary disease (COPD) [11–13]. The earliest
smoking-induced abnormalities in the small airway epithelium
include alterations of the cell cycle, repair and apoptosis, and a
variety of changes resulting from oxidative stress [5,7,14]. In
smokers who develop disease, there is epithelial dysfunction, leading
to impaired mucociliary clearance, abnormalities in host defense,
chronic colonization by pathogens, and mucus obstruction [14–17].
The airway epithelium of apparently healthy smokers demon-
strates marked changes in gene expression compared to nonsmokers
[18–22]. With the knowledge that, on average, smokers have an
abnormal biologic phenotype of the small airway epithelium [21], but
smoking causes disease in only a fraction of smokers, we asked two
questions. First, is the gene expression profile of the small airway
epithelium consistent among smokers, or do smokers exhibit variable
gene expression profiles of the small airway epithelium, and if so, can
this be used to categorize healthy smokers into biologic phenotypes?
Second, to what extent, if any, do these biologic phenotypes of the
small airway epithelium of healthy smokers overlap with those of the
small airway epithelium of COPD smokers?
To assess these concepts, Affymetrix HG-U133 Plus 2.0
microarrays were used to evaluate small airway gene expression
of healthy nonsmokers, healthy smokers and smokers with COPD.
Comparison of the average small airway epithelium gene
expression in healthy smokers vs nonsmokers identified 647 probe
sets representing 375 unique known genes significantly differen-
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observed among healthy smokers and allow biologic subcategori-
zation of smokers, an index was calculated for overall small airway
epithelium gene expression (ISAE) for each individual, representing
the percentage of the 375 differentially expressed genes for which
that individual’s expression was abnormal (increased or sup-
pressed), defined as more than 2 standard deviations from the
mean in healthy nonsmokers. Not only did the ISAE clearly
discriminate smokers from nonsmokers, but it allowed subcatego-
rization of healthy smokers based on the magnitude of the
response to the stress of smoking, ranging from a ‘‘high’’ response
with differential expression of hundreds of genes, to a ‘‘low’’
response with a gene expression profile close to that of
nonsmokers. Interestingly, although high vs low responder healthy
smokers have different small airway epithelial transcriptomes, and
low responder healthy smokers have different small airway
epithelial transcriptomes from COPD smokers, comparison of
the gene expression profiles of the COPD smokers and high
responder healthy smokers showed no differences. Together, these
findings indicate that small airway epithelial gene expression can
be used to phenotype clinically healthy smokers at a biologic level,
a strategy that should be useful in helping to identify those smokers
that may progress to develop airway disease.
Some of these results have been previously reported in the form
of an abstract [23].
Methods
Study Population
All individuals were evaluated at the Weill Cornell NIH
Clinical and Translational Science Center and Department of
Genetic Medicine Clinical Research Facility, under clinical
protocols approved by the Weill Cornell Medical College
Institutional Review Board. All subjects provided written consent
before any study procedures were undertaken. Healthy non-
smokers (n=63; 47 in a primary set and 16 in a validation set)
and healthy current cigarette smokers (n=72; 58 in a primary set
and 14 in a validation set) were recruited from the general
population in New York City by posting advertisements in local
newspapers and on electronic bulletin boards. Individuals with
COPD (n=36, 22 in a primary set and 14 in a validation set; all
current smokers) were recruited in the same way and also from
the outpatient clinics of the Division of Pulmonary and Critical
Care Medicine.
Individuals were determined to be phenotypically normal or to
have COPD based on standard history, physical exam, complete
blood count, coagulation studies, liver function tests, urine studies,
chest X-ray (and, where relevant, chest CT scan), EKG and
pulmonary function tests. The GOLD criteria [13], based on post-
bronchodilator FEV1/FVC ratio ,70%, were used to define and
stage COPD. Full inclusion/exclusion criteria are detailed in Text
S1. This study is registered under the ClinicalTrials.gov identifiers
NCT00224185 and NCT00224198.
Sampling Airway Epithelium, RNA and Microarray
Processing
Collection of small airway epithelial cells by fiberoptic
bronchoscopy and extraction and processing of RNA for
microarray analysis were carried out as previously described [21]
(for full details, see Text S1).
Web Deposition of Data
The raw data are all publicly available at the MIAME-
compliant Gene Expression Omnibus (GEO) site (http://www.
ncbi.nlm.nih.gov/geo/), a high-throughput gene expression/
molecular abundance data repository curated by the National
Center for Bioinformatics (NCBI) site, accession number
GSE11784. Subsets of these samples have been used in unrelated
analyses in other published manuscripts [21,24–29]. The GEO
accession numbers for the samples in the validation set (n=16
nonsmokers, n=14 healthy smokers and n=14 COPD smokers)
are shown in Table S1.
Microarray Data Analysis - General
Microarray data were processed using the MAS5 algorithm
(Affymetrix Microarray Suite Version 5 software), which takes into
account the perfect match and mismatch probes. MAS5-processed
data were normalized using GeneSpring by setting measurements
,0.01 to 0.01 and by normalizing per chip to the median
expression value on the array. Genes that were significantly
modified by smoking were selected from the primary set of
nonsmokers (n=47) and healthy smokers (n=58) according to the
following criteria: (1) P call of ‘‘Present’’ in $20% of samples
[19,21,22,30]; (2) magnitude of fold change in average expression
value for healthy smokers vs nonsmokers $1.5 [31–35]; and (3)
p,0.01 using a t-test with a Benjamini-Hochberg correction to
limit the false positive rate [36], except for the analysis of COPD
smokers vs high and low responder healthy smokers in the
validation set, in which due to lower sample size p,0.05 with a
Benjamini-Hochberg correction was considered significant. Func-
tional annotation was carried out using the NetAffx Analysis
Center (www.affymetrix.com) to retrieve the Gene Ontology (GO)
annotations from the National Center for Biotechnology (NCBI)
databases. For genes without GO annotations, other public
databases were searched (Human Protein Reference Database,
Kyoto Encyclopedia of Genes and Genomes, PubMed).
This analysis generated a list of 647 probe sets representing
375 known genes that were significantly differentially expressed
on average in healthy smokers vs healthy nonsmokers. This gene
list was validated using unsupervised cluster analysis on these
genes in the validation samples from nonsmokers (n=16) and
healthy smokers (n=14). Additionally, the selection of genes was
verified to be stable to normalization and specific technique by
using singular value decomposition (SVD) [37] and prediction
analysis of microarrays (PAM) [38] as additional methods to
select genes that discriminated smokers from nonsmokers, to
verify that the genes discriminating smokers from nonsmokers
were robust with respect to method. Further details of these
methods are in Text S1.
TaqMan PCR was used to confirm expression levels of selected
smoking-responsive genes. For full details, see Text S1.
Index of Airway Gene Expression
The gene expression index for small airway epithelium (ISAE)
was calculated using the 375 smoking-responsive genes. For genes
represented by more than one probe set, the probe set with the
lowest p value was used. Expression values were log2 transformed.
For each gene, a mean and standard deviation were calculated
from the values in nonsmokers, and the normal range was defined
as within 2 standard deviations of the mean, in the direction of the
smoking-induced change (i.e., for smoking-suppressed genes, the
threshold for normal equals the mean minus 2 standard deviations
and for smoking-induced genes the threshold for normal equals the
mean plus 2 standard deviations). The number of genes expressed
outside the normal range was summed for each individual and
divided by 375, the number of genes represented by the index. For
the small airway epithelium, therefore,
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where E1 has a value of 1 if the expression level for gene 1 is .2
SD above or below that of healthy nonsmokers or has a value of 0
if the expression level is #2 SD above or below that of healthy
nonsmokers; E2 is the index for gene 2, etc., and the constant
(c=100/375) normalizes the index to the percent of the 375 genes
that are outside of the range of healthy nonsmokers.
To establish ‘‘high’’ and ‘‘low’’ responder phenotypes of healthy
smokers, the smokers were divided into two groups based on the
ISAE values. The healthy smokers with index values less than or
equal to the median were categorized as ‘‘low’’ responders and
those above the median were labeled ‘‘high’’ responders to the
stress of smoking. To assess the stability of the ISAE over time, a
subset of healthy nonsmokers (n=7) and healthy smokers (n=6)
underwent bronchoscopy at a second time point 1 to 25 months
from the 1
st bronchoscopy. Only data from the first bronchoscopy
were used in the analysis of smoking-responsive genes and the
development of the ISAE metric. To evaluate stability over time,
the ISAE was calculated separately on data from each individual’s
2
nd bronchoscopy. The ISAE was further evaluated in terms of
distribution among phenotypic groups, potential confounders,
robustness and sampling properties, and robustness of the
classification of high and low responder smokers; these analyses
are described in Text S1.
Subgroup Analyses
Having defined subgroups of low and high responder smokers
based on the ISAE, the genome-wide gene expression of the
subgroups of low and high responder healthy smokers was
compared to each other and to the independent group of COPD
smokers. Criteria for significantly changed genes were as described
above. These analyses were carried out using the groups of high
and low responders defined by the median ISAE, as described
above, and were repeated using a different classification in which
the highest 20% of ISAE values were considered high responders
and the remaining 20% considered low responders.
Principal components analysis was performed using R (The R
Foundation for Statistical Computing, version 2.5.1) to compare
small airway epithelial gene expression for high vs low responder
healthy smokers using log2-transformed expression values for the
differentially expressed genes. The data were visualized by plotting
on a two-dimensional graph representing the first two principal
components.
Results
Study Population and Biologic Samples
The primary study population of 127 individuals included 47
nonsmokers, 58 healthy smokers and 22 smokers with COPD
(GOLD I, n=9; GOLD II, n=11; and GOLD III, n=2; Table 1).
The three groups were of similar distribution of gender
(predominately male, p.0.3, Chi-square) and race (mostly of
African or European descent, p.0.2, Chi-square). The COPD
group was older (p,0.001) than the two other groups. The lung
function of the normal nonsmokers and normal smokers was
similar (p.0.07, all comparisons). On the average, smokers with
COPD reported more pack-yr of smoking (p,0.05). Smokers with
COPD had a reduced FEV1 (% predicted) and FEV1/FVC (%
observed), consistent with the definition of COPD [13], and a
reduced DLCO (% predicted) compared to the normal nonsmok-
ers and smokers (p,0.0001, all comparisons). Among the 22
COPD smokers, 7 were on medications for COPD (2 of 9 GOLD
I, 3 of 11 GOLD II, and 2 of 2 GOLD III). The classes of
medications included short- and long-acting b-agonists, short- and
long-acting anticholinergics, inhaled corticosteroids, systemic
corticosteroids and theophylline; several of those treated were on
multiple classes of medications. The total number of cells
recovered by brushing was similar in all groups (p.0.07). The
percent epithelial cells recovered was, on average, $98% in all
groups. Smokers with and without COPD had fewer ciliated cells,
more secretory cells, and more undifferentiated cells than
nonsmokers (p,0.01 for all). Among all samples, the average
RNA yield was 24.1610.8 mg/subject. The validation population
of nonsmokers, healthy smokers and COPD smokers was similar
to the primary population in all of these respects (Table 1).
Effect of Smoking on Gene Expression in the Small
Airway Epithelium
Comparing healthy smokers to healthy nonsmokers, 647 probe
sets were identified as having expression levels significantly
responsive to smoking (Figure 1A, Table S2). The identified probe
sets were groupedintofunctional categories based on annotations in
public databases and literature review. The specific categories
containing the greatest numbers of changed genes were metabolism
and transport. In contrast, the xenobiotic and oxidant-related
category contained the genes displaying the greatest magnitude of
change in expression levels in healthy smokers (Figure 1B).
Three methods were used to validate the smoking signature.
First, unsupervised cluster analysis was carried out using this
signature on the independent validation set of normal nonsmokers
(n=16) and normal smokers (n=14). This analysis showed strong
separation of smokers from nonsmokers based on expression of the
smoking signature genes (Figure 1C). In addition, both singular
value decomposition (SVD) and prediction analysis of microarrays
(PAM) were used to independently select genes differentially
expressed between smokers and nonsmokers (Figure 1D). Genes
identified by these methods showed significant overlap with the
initial 647 probe sets identified by t-test. Of 300 probe sets
identified by SVD, 215 (72%) overlapped with the t-test probe sets,
including 96 of the top 100 genes identified by SVD. Of 190 probe
sets identified by PAM, 188 (99%) were identified by t-test.
TaqMan real-time RT-PCR was used to confirm expression
levels of six representative smoking-responsive genes identified in
the healthy smoker vs nonsmoker analysis, including cytochrome
P450, family 1, subfamily B, polypeptide 1 (CYP1B1), transcrip-
tion factor 7-like 1 (TCF7L1), aldo-keto reductase family 1,
member B10 (AKR1B10), ubiquitin carboxyl-terminal esterase L1
(UCHL1), calcitonin-related polypeptide alpha (CALCA) and
NAD(P)H dehydrogenase, quinone 1 (NQO1). For each, RT-PCR
confirmed the smoking-induced change in expression observed
using the microarrays (Table S3).
To evaluate the difference between the smoking response of the
small airways compared to the large airways, the 375-gene
smoking signature was evaluated for overlap with other published
smoking signature gene lists from the large airway epithelium.
Spira et al [19] described genes differentially expressed in the large
airway epithelium of 34 current smokers and 23 never smokers. Of
the 375 SAE smoking signature genes, 38 (10%) were also present
in the Spira et al [19] large airway epithelium analysis (Table S3).
Zhang et al [39] described 145 unique genes differentially
expressed in the large airway epithelium of 56 current smokers
vs 24 former smokers, and 92 genes differentially expressed in 56
current vs 19 never smokers. Of the 375 SAE smoking signature
genes, 53 (14%) were present in current/former smoker analysis,
Smoking Phenotype of the Small Airway Epithelium
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(Table S4). Thus, while there is some overlap among these studies,
the SAE transcriptome in healthy smokers and healthy nonsmok-
ers revealed a large set of novel genes different from that observed
in the large airway epithelium.
Variability of Gene Expression in Healthy Smokers
Significant variability in gene expression was seen among the
healthy smokers (Figure S1). For example, for protein phosphatase 1,
regulatory (inhibitor) subunit 16B (PPP1R16B), the variance of the
log2-transformed expression values inhealthy smokerswas1.8 vs 0.4for
nonsmokers (p,0.0001); for chondroitin sulfate N-acetylgalactosami-
nyltransferase 1 (CSGALNACT1), the variance in healthy smokers
was 1.1 vs 0.5 for nonsmokers (p,0.01); for glutathione peroxidase 2
(GPX2), the variance in healthy smokers was 1.0 vs 0.3 for nonsmokers
(p,0.0002); and for cytochrome P450, family 1, subfamily A,
polypeptide 1 (CYP1A1), the variance in healthy smokers was 9.1 vs
1.2 for nonsmokers (p,0.0001). Consequent to this variation, each
individual healthy smoker expressed some genes above or below 2
standard deviations from the mean of the healthy nonsmokers, but this
varied from gene to gene for each individual. In the examples shown,
one individual healthy smoker (indicated by the arrow) expressed
CSGALNACT1 and CYP1A1 within the range of the nonsmokers,
but expressed PPP1R16B and GPX2 outside of the range of the
nonsmokers.
ISAE in Healthy Smokers vs Healthy Nonsmokers
The 375 smoking-responsivegenes were used to establishthe small
airway gene expression index (ISAE) by assessing for each individual
the percent of these genes that were abnormally expressed by that
Table 1. Demographics of the Study Population and Biologic Samples
1.
Primary Set Validation Set
Parameter
Healthy
nonsmokers
Healthy
smokers
Smokers with
COPD
2
Healthy
nonsmokers
Healthy
smokers
Smokers with
COPD
n 4 7 5 8 2 2 1 61 41 4
Sex (male/female) 33/14 38/20 18/4 7/9 14/0 10/4
Age (yr) 42.4611.2 42.967.2 51.568.5 36.5612.8 40.769.1 50.265.4
Race (B/W/O)
3 23/18/6 35/14/9 8/9/5 4/6/6 9/2/3 5/4/5
Smoking history (pack-yr) - 27.5616.7 41.0628.2 - 23.8612.1 34.9613.5
Urine nicotine (ng/ml) - 128361580 11226773 - 159661359 213261658
Urine cotinine (ng/ml) - 13036988 241061436 - 156861257 17326743
Blood carboxyhemoglobin (%) - 2623 62- 1 613 62
Pulmonary function parameters
4
FVC 107613 109613 97621 107610 112611 115617
FEV1 107614 109615 71621 104611 107611 95616
FEV1/FVC 82668 1 656 1 688 2 657 8 646 6 64
TLC 100614 100612 101622 94611 102614 111614
DLCO 99614 93611 75619 94612 93610 80612
Gold stage (I/II/III)
2 - - 9/11/2 - - 10/2/0
Medication use
b-agonist - - 7 - - 1
Anticholinergic - - 2 - - 0
Inhaled corticosteroid - - 3 - - 0
Epithelial cells
5
Number recovered 610
6 6.061.9 7.263.0 6.863.6 7.463.1 8.564.1 5.761.7
% epithelial cells 99.361.1 99.161.3 98.961.4 97.861.6 98.061.8 97.861.3
% inflammatory cells 0.761.1 0.961.3 1.161.4 2.261.6 1.961.8 2.161.4
Differential cell count
6
Ciliated (%) 74.367.4 65.6612.6 63.5610.9 65.069.2 57.066.8 56.168.4
Secretory (%) 6.663.5 9.164.6 11.965.6 6.964.0 5.862.8 10.765.5
Basal (%) 11.165.3 12.866.7 11.966.3 16.668.1 20.5610.2 19.669.1
Undifferentiated columnar (%) 7.363.2 11.966.7 11.663.7 9.163.8 14.466.9 11.464.7
1Data are presented as mean 6 standard deviation.
2Smokers with ‘‘established COPD’’ defined by the GOLD criteria (13); the COPD smoker group included: GOLD I n=9, GOLD II n=11, and GOLD III n=2.
3B=black, W=white, O=other.
4Pulmonary function testing parameters are given as % of predicted value with the exception of FEV1/FVC, which is reported as % observed; FVC - forced vital capacity,
FEV1 - forced expiratory volume in 1 sec, TLC - total lung capacity, DLCO - diffusing capacity. For individuals with COPD, FVC, FEV1, and FEV1/FVC are post-
bronchodilator values.
5Small airway epithelium.
6As a % of small airway epithelium recovered.
doi:10.1371/journal.pone.0022798.t001
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(median 1.1%; Figure 2A; TableS5). Theseindex values ranged from
0% (minimum) to 14.7% (maximum) in the K-fold analysis,
indicating that the range of ISAE for this group was robust to the
effects of sampling. In contrast, healthy smokers demonstrated
significantly higher ISAE values, ranging from 2.9% to 51.5% (median
23.6%, p,0.0001 healthy smokers vs nonsmokers; Figure 2A; Table
S4). The range of these values was likewise robust to sampling effects,
from 1.9% (minimum)to 60.0%(maximum) in the K-fold analysis, in
which ISAE values were computed using normal gene expression
ranges calculated from subgroups of nonsmokers. The variability in
ISAE among healthy smokers was significantly greater than that
among nonsmokers (variance for healthy smokers 109.4, for
nonsmokers 5.8, p,0.0001). For further analysis, the healthy smokers
were divided by ISAE value into low responders, those with ISAE
values at or below the median, and high responders, those with ISAE
values above the median.
There was no relationship of the ISAE values with gender,
ancestry, pack-yr smoked, smoking duration in years, FEV1,
FEV1/FVC, or FEF25–75. There was a relationship between the
Figure 1. Differential gene expression profiles in the small airway epithelium in nonsmokers and healthy smokers. Expression levels
normalized by array were compared for n=58 healthy smokers and n=47 healthy nonsmokers for all probe sets ‘‘present’’ in at least 20% of samples.
A. Volcano plot. The mean expression level for healthy smokers vs healthy nonsmokers was assessed for fold-change (abscissa) vs p value (ordinate)
by t-test. Each probe set is represented by a filled circle, with probe sets that are not significantly different in healthy smokers compared to healthy
nonsmokers in gray and those that are significantly different in the 2 groups in red. Probe sets with a higher expression level in healthy smokers are
to the top right and those with a lower expression level in healthy smokers are to the top left. There are 647 probe sets representing 375 known
genes that are significantly up- and down-regulated by smoking. Only probe sets corresponding to known genes were used to construct the index
for small airway epithelium gene expression (ISAE). When there is more than one probe set for a given gene, the decision as to which probe set is used
for further analysis was made as described in Methods. B. Categories of genes differentially modified by smoking in the small airway epithelium.
Shown is a skyscraper plot of fold-changes (log2 scale) for probe sets significantly differentially expressed in healthy smokers vs nonsmokers. Known
genes significantly up-regulated in healthy smokers have fold-changes .1; those significantly down-regulated in healthy smokers have fold-changes
,1. Alternating gray and white bands highlight the probe sets belonging to specific functional categories. C. Unsupervised cluster analysis. Probe
sets expressed above average are represented in red, below average in blue, and average in white. Each row represents one of the 375 smoking-
responsive genes used in the index, and each column represents an individual subject from the validation set of healthy nonsmokers and healthy
smokers. Healthy smokers (n=14) are indicated by orange, healthy nonsmokers (n=16) by green. D. Venn diagram. Smoking-responsive probe sets
identified by the main, t-test analysis (647 probe sets) are represented in blue, probe sets identified by singular value decomposition (SVD, 300 probe
sets) in yellow, and probe sets identified by prediction analysis of microarrays (PAM, 190 probe sets) in pink. The intersection of the ovals represents
the overlap between genes selected using each method, i.e., 87 genes are smoking-responsive in the t-test and SVD analyses (green), 60 probe sets
overlap between the t-test and PAM analyses (purple), and 128 genes were significant in all 3 analyses (brown).
doi:10.1371/journal.pone.0022798.g001
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using a Kruskal-Wallis test (p,0.02), but a linear regression model
was not significant (p.0.1) and the amount of variation in ISAE
with age was minimal (,3%) and thus it is unlikely that age was an
important factor influencing the observed trends. Assessment of
possible effects of hybridization date among healthy nonsmokers
and healthy smokers using a Kruskal-Wallis test showed no
significance. In addition, demographic information, smoking-
related parameters, lung function parameters, numbers of cells
collected and differential cell counts were examined for low
responder vs high responder healthy smokers (Table S6; data for
pack-yr and years of smoking is shown in Figure S2). There were
no statistically significant differences in the two groups for any of
these parameters adjusting for multiple testing.
ISAE Stability Over Time
To evaluate the stability of the ISAE over time, a subset of
nonsmokers (n=7) and healthy smokers (n=6) underwent repeat
bronchoscopies at times ranging from 1 to 25 months (1367
months) and ISAE was calculated at these subsequent time points
(Figure 2B). All nonsmokers’ ISAE values at time 0 were ,5%, and
ISAE remained ,5% for each nonsmoker at the repeat
bronchoscopy. Among the healthy smokers, 4 individuals were
low responders at time 0 and remained low responders at the 2
nd
evaluation, and 2 individuals were high responders at time 0 and
remained high responders at the 2
nd evaluation.
ISAE Allows Meaningful Phenotyping of Healthy Smokers
To evaluate whether high responder smokers represent a group
with small airway epithelial gene expression that is clearly distinct
from that of low responder smokers, genome-wide expression
analysis (i.e., using all genes, not only the smoking-responsive
genes) was used to compare these two groups. Thirty-eight probe
sets representing 29 genes were found to be significantly
differentially expressed. As expected, 26 probe sets (representing
21 genes) were members of the smoking-responsive set of genes
used to categorize smokers as low and high responders. However,
this analysis also revealed 12 independent probe sets representing
8 genes significantly differentially expressed in the two groups
(Table S7). Cluster analysis using the 38 significant probe sets
showed clear separation of the independent group of high vs low
responder smokers in the validation set (n=14; 9 low responders
and 5 high responders) (Figure 3A). Principal components analysis
was consistent with cluster analysis and also showed clear
separation of the high and low responders from the independent
test set (Figure 3B). The K-fold analysis of these groups indicated
that individual classification was robust to sampling effects, with
90% of smoking individuals consistently classified as ‘‘high’’ or
‘‘low’’ responders in .75% of samples.
To evaluate whether the classification of high and low
responder smokers was robust to the analytic method used, we
assessed three additional methods to subcategorize healthy
smokers and evaluated whether those classifications were similar
to the index-based classification. First, singular value decomposi-
tion was performed using all 647 smoking-responsive probe sets as
a principal components analysis on the 58 smokers. In this
analysis, the first principal component corresponded to the
separation of the high and low responder smokers. These two
groups showed significant separation (p,0.0001) and this principal
component captured 26.7% of the variability in the data. Second,
prediction analysis of microarrays (PAM) was carried out using the
647 smoking-responsive probe sets for all healthy smokers. This
assessment showed correct classification of 79.5% of samples,
which could be increased to 87.5% accuracy using a reduced
centroid of 53 genes. Finally, we performed a support vector
machine (SVM) analysis and were able to categorize high and low
responder smokers with 76.0% accuracy.
Comparison of Small Airway Epithelial Gene Expression in
Healthy Smokers vs COPD Smokers
Global gene expression was compared between COPD smokers
and the two subgroups of healthy smokers, low and high
responders (Figure 4). When COPD smokers were compared to
only the subgroup of low responder smokers, a total of 92 probe
sets, representing 75 genes, were significantly differentially
expressed (Figure 4A, Table S8). In marked contrast, analysis of
COPD smokers vs high responder smokers revealed no differences
in genome-wide gene expression (Figure 4B). This trend was also
reflected in the ISAE of COPD smokers, as 88.0% of COPD
smokers had an ISAE value within the range of high responder
smokers, and 95.5% were similarly classified in .75% of the K-
fold samples.
Figure 2. Index for small airway epithelial gene expression
(ISAE). A. ISAE values for nonsmokers (white circles, n=47) and healthy
smokers (graycircles, n=58). Thedashed line demarcates the medianISAE
value for the healthy smokers. Individuals with lower ISAE demonstrate
abnormal expression of relatively few smoking-responsive genes, and
individuals with the highest ISAE values abnormally express the greatest
numbers of smoking-responsive genes. Individuals below the median are
termed‘‘low’’ respondersandthoseabovethe median ‘‘high’’ responders
to the stress of smoking. B. Assessment of stability of the ISAE over time.
Healthynonsmokers(n=7,whitecircles)andhealthy smokers (n=6,gray
circles) had assessments of ISAE at time 0 and again at times up to nearly
25 months. All nonsmokers had ISAE values that remained ,5%. Among
the healthy smokers, 4 low responders remained low responders and 2
high responders remained high responders over time.
doi:10.1371/journal.pone.0022798.g002
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in the small airway similar to high responder smokers, and on the
knowledge that only 15 to 20% of smokers develop COPD,
genome-wide gene expression was also compared for COPD
smokers vs the top 20% of smokers based on ISAE, and for COPD
smokers vs the bottom 20% of smokers based on ISAE. Consistent
with the analysis with the high and low responders based on
separation by the median, there were no significant differences
between COPD smokers and the top 20% of healthy smokers
based on ISAE. The analysis of expression of COPD smokers vs the
bottom 80 20% of smokers revealed 85 probe sets representing 65
unique genes significantly differentially expressed between these
two groups (Table S8). This observation was replicated in an
independent test set of COPD smokers (n=14) compared to high
responder smokers (n=5) and low responder smokers (n=5).
While this test set had reduced power compared to the larger
primary set, consistent with the data from the primary set, there
were no expression differences between the COPD smokers and
high responder healthy smokers, whereas 18 probe sets represent-
ing 16 genes were differentially expressed between COPD smokers
and low responder healthy smokers.
Figure 3. Genome-wide gene expression in the small airway
epithelium of high vs low responder healthy smokers. Differen-
tially expressed genes were evaluated in the primary set of healthy
smokers (n=29 in each group) and the signature evaluated in the
validation set of healthy smokers (n=14 total; 9 low responders and 5
high responders based on the median ISAE observed in the primary
analysis). A. Cluster plot. Probe sets expressed above average are
represented in red, below average in blue, and average in white. Each
row represents one probe set, or gene, and each column represents an
individual subject. High responder healthy smokers are indicated by
orange, low responder healthy smokers by yellow. B. Principal
components analysis of gene expression in high responder and low
responder healthy smokers. Each axis represents one principal
component (PC), with PC1 on the x axis and PC2 on the y axis. Low
responder healthy smokers are represented by yellow dots and high
responder healthy smokers by orange dots.
doi:10.1371/journal.pone.0022798.g003
Figure 4. Genome-wide gene expression in the small airway
epithelium of COPD smokers (n=22) vs high and low
responder subgroups of healthy smokers (n=29 in each
group). A. Volcano plot of COPD smokers vs low responder healthy
smokers. The mean expression level for COPD smokers vs low
responder healthy smokers was assessed for fold-change (abscissa) vs
p value (ordinate) by t-test. Each probe set is represented by a filled
circle, with probe sets that are not significantly different in COPD
smokers compared to low responder healthy smokers in gray and those
that are significantly different in the 2 groups in red. Probe sets with a
higher expression level in COPD smokers are to the top right and those
with a lower expression level in COPD smokers are to the top left. There
are 92 probe sets representing 75 known genes that are significantly
up- and down-regulated in COPD smokers vs low responder healthy
smokers. B. Volcano plot of COPD smokers vs high responder healthy
smokers. The mean expression level for COPD smokers vs high
responder healthy smokers was assessed for fold-change (abscissa) vs
p value (ordinate) by t-test. Probe sets that are not significantly different
in COPD smokers compared to high responder healthy smokers are
shown in gray and those that are significantly different in the 2 groups
in red. Probe sets with a higher expression level in COPD smokers are to
the top right and those with a lower expression level in COPD smokers
are to the top left. Genome-wide, no probe sets were significantly
different in COPD smokers compared to high responder healthy
smokers.
doi:10.1371/journal.pone.0022798.g004
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biomarker to distinguish low responder smokers from high
responder and COPD smokers, we combined high responder
and COPD smokers and compared genome-wide gene expression
in this group vs. in the low responder healthy smokers. This
analysis revealed 294 probe sets representing 238 unique genes
significantly differentially expressed between these two groups
(Table S9). Cluster analysis was carried out using this 294 probe
set signature on the independent validation set of healthy smokers
(n=14; n=5 high responders and n=9 low responders) and
COPD smokers (n=14). The cluster analysis showed no
separation between high responder smokers and COPD smokers
and separation of those groups from the low responder smokers,
with the exception of one high responder smoker who clustered
with low responders, and one low responder who clustered with
high responder/COPD smokers (Figure S3A). Similarly, principal
components analysis on the independent test set using this 294
probe set signature showed overlap of high responder and COPD
smokers with this combined group clearly separating from the low
responder healthy smokers (Figure S3B).
Discussion
Cigarette smoking is the major cause of COPD, yet only a
minority of smokers develop the disease. Based on the knowledge
that cigarette smoking can induce changes in the expression of
hundreds of genes in the airway epithelium [18–22], and that the
small airway epithelium is the earliest site of smoking-induced
COPD [21], we hypothesized that gene expression in the small
airway epithelium could be used to construct a biologic phenotype
that quantifies the individual smoker’s response to cigarette
smoking. The analysis identified genes that distinguished healthy
smokers from nonsmokers and validated that smoking signature
using unsupervised cluster analysis on an independent group of
samples, as well as by using singular value decomposition and
prediction analysis of microarrays methods to independently select
smoking signature genes and confirm that the smoking signature
genes were nearly the same regardless of method. The data
demonstrate that although healthy smokers clearly segregate from
healthy nonsmokers, the healthy smokers have variable gene
expression patterns. To quantify this observed variability, we
developed an index of small airway epithelial gene expression (ISAE)
that quantifies the number of smoking-responsive genes up- or
down-regulated in any given individual. The ISAE separates healthy
smokers from healthy nonsmokers and numerically captures the
considerable variability in gene expression in the small airway
epithelium among healthy smokers. This permits identification of
‘‘high’’ responders to smoking, who show up- and down-regulation
of hundreds of genes, and ‘‘low’’ responders with gene expression
profiles closer to those of nonsmokers. These categories were robust
to the effects of sampling, and reassessment of a subset of these
individuals showed stability of the small airway epithelial tran-
scriptome for each individual over time. Genome-wide analysis of
the small airway epithelium of high vs low responding healthy
smokers revealed differences in both smoking-responsive and
smoking-independent genes. Interestingly, genome-wide analysis
of COPD smokers vs low responder healthy smokers identified
differences in expression of a significant number of genes, but
genome-wide analysis of COPD smokers vs high responder healthy
smokers identified no significant differences in expression, i.e., the
small airway epithelial transcriptomes of COPD smokers and high
responder healthy smokers are indistinguishable. This was corrob-
orated by analysis in the independent test set of COPD smokers and
healthy smokers, although that data set was smaller and had less
power to detect differences. Because of this limitation, we further
corroborated this finding by constructing a gene expression
biomarker in the primary set to differentiate low responder healthy
smokers from COPD and high responder smokers, and used that
signature to differentiate these groups in the independent test set of
subjects. Although it will take long term followup of large numbers
of healthy smokers over many years to determine the fate of ‘‘high’’
and ‘‘low’’ responder healthy smokers, the data demonstrate that
analysis of the small airway epithelial transcriptome can be used to
subclassify clinically healthy smokers into biologic phenotypes with
lesser and greater responses to the insult of cigarette smoke, even
though these subgroups are indistinguishable by conventional
clinical criteria.
Smoking and the Airway Epithelial Transcriptome
Several studies have demonstrated that smoking significantly
affects the transcriptome of the airway epithelium. Most studies
have used the large airway epithelium (0 to 5
th generations) as the
source of the biologic material. Spira et al [19], and studies from
our laboratory [18], have shown variable up- and down-regulation
of a number of genes in the large airway epithelium of smokers
compared to nonsmokers, while Zhang et al [39] described
differences in gene expression in the large airway epithelium of
current smokers vs both never smokers and former smokers. Beane
et al [20] showed that while the large airway epithelial expression
of many smoking-responsive genes is reversible upon smoking
cessation, there are a number of smoking-responsive genes with
persistently abnormal expression after smoking cessation. Pierrou
et al [22] found significant changes in the expression of oxidant-
related genes in the large airway epithelium of nonsmokers,
healthy smokers and COPD smokers, as did the study by Hackett
et al [18] of nonsmokers vs healthy smokers. A number of studies
have examined gene expression in whole lung samples of
individuals with COPD, rather than airway epithelium per se.
Ning et al [40] used both serial analysis of gene expression and
microarray technology to detect gene expression differences
between GOLD-2 and GOLD-0 lung. Wang et al [41] found
altered expression of genes relating to tissue remodeling and repair
in samples of lung parenchyma of individuals with COPD
compared to nonsmokers. Spira et al [30] and Golpon et al [42]
identified changes in gene expression in emphysematous lung
tissue compared to normal or mildly emphysematous lung. Finally,
the use of airway epithelial gene expression as a biomarker for
cancer risk has been explored by Spira et al [43], who developed
an 80-gene biomarker that distinguishes between smokers with
and without lung cancer based on large airway epithelial gene
expression patterns.
While all of these large airway epithelial and whole lung
transcriptome studies provide useful information, the small airway
epithelium (airways,2 mm,6
thto23
rdgenerations)isthesite ofthe
earliest abnormalities associated with smoking relevant to COPD,
including morphologic changes and alterations of cell cycle, repair,
apoptosis and response to oxidative stress [5,7,15–17]. Hogg et al
[5,44] have shown that the small airways are the earliest site of
morphologic changes in COPD, and that progression of COPD is
strongly associated with local changes in the small airways.
Therefore, in strategizing to develop a biologic phenotype to
subcategorize healthy smokers we assessed the transcriptome of the
small airway epithelium, the site where the disease begins [21].
ISAE as a Biologic Phenotype
The ISAE is a metric of gene expression for the small airway
epithelium that describes, for each individual, the percent of
smoking-responsive genes that are abnormally expressed. The ISAE
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a descriptor by which to quantify the variability in responsiveness
to cigarette smoking at the level of small airway epithelial gene
expression. Interestingly, some healthy smokers have gene
expression profiles quite similar to those of healthy nonsmokers
(‘‘low’’ responders) whereas others have remarkably different
patterns of gene expression compared to healthy nonsmokers
(‘‘high’’ responders). The ISAE appears to be robust to the effects of
sampling and stable over time, with 6 of 6 healthy smokers
retaining their original designation as high or low responders over
time periods ranging from 1 to .20 months. When healthy
smokers are subgrouped into high and low responders, interesting
patterns emerge in genome-wide expression. Significant differenc-
es are found between high and low responder healthy smokers,
and between COPD smokers and low responder healthy smokers,
but no differences are found between COPD smokers and high
responder healthy smokers.
The data in the present study support the hypothesis that there
is biologic variation at the level of gene expression in the small
airway epithelium among a population of healthy smokers, and
that a subpopulation of the healthy smokers have a small airway
epithelial transcriptome similar to that of smokers with clinical
evidence of COPD. If this is true, how can this be reconciled with
data showing differences in gene expression in COPD smokers
compared to healthy smokers? One explanation, supported by the
data in the present study, is that while there are differences with
COPD smokers when considering healthy smokers as a homog-
enous group, when the healthy smokers are subgrouped as high
responders and low responders, there are differences only between
the COPD smokers and low responders, but not between COPD
smokers and high responders. Consistent with this hypothesis, we
re-analyzed data from the subjects in a previous publication in
which we demonstrated differences in expression of genes related
to the Notch pathway between healthy smokers and smokers with
COPD [29]. Calculation of ISAE in this population revealed that
the majority (60%) of the healthy smoker population were low
responders, who would be expected to have greater differences in
gene expression compared to COPD smokers than would high
responder smokers.
Caveats do apply to our study. First, while the ISAE appears to
be robust to the effects of sampling, and consistent in the subset of
individuals reevaluated at a later time, to our knowledge, there are
no other publicly available data sets of gene expression in the small
airway epithelium, and thus our observations will need to be
replicated by other investigators. Second, the ISAE, reflecting only
gene expression changes in epithelial cells, likely does not capture
all of the biology of COPD, which involves other cell types,
including endothelial cells and inflammatory cells beneath the
epithelial basement membrane. However, since small airway
epithelial cells show the first morphologic changes relevant to
COPD [5,44], we chose to develop the ISAE based on gene
expression changes in those cells. Finally, the concept that high
responder smokers might be at higher risk for COPD is a
hypothesis; proof will require large numbers of subjects to be
followed for decades. It has recently been suggested that variations
in individual responses to cigarette smoking may underlie the
different clinical and molecular phenotypes and variable natural
history associated with COPD [45]. We believe this to be true, and
we suggest that the small airway epithelial gene expression
phenotype quantified in the ISAE may have biologic significance,
i.e., that the group of smokers that manifests the highest response
of gene expression in the small airway epithelium, though clinically
healthy, are biologically different from individuals with low
responses to smoking, may respond to therapy differently, and
may have different prognoses. In this context, the ISAE represents a
tool for characterizing phenotype among smokers that could be
prospectively examined in epidemiologic studies. This may prove
useful for risk assessment and prognosis for individual patients, as
well as in therapeutic trials as a surrogate outcome measure.
Supporting Information
Figure S1 Examples of variable response of the human
small airway epithelium to smoking. Arrows indicate how
this is used to construct the index for small airway epithelium gene
expression (ISAE). Each circle represents log2 transformed gene
expression for one individual, with healthy nonsmokers (n=47) on
the left and healthy smokers (n=58) on the right in each graph.
The gray shaded area represents the mean expression value in
healthy nonsmokers 62 standard deviations. Open circles
represent expression values within the 2 standard deviations of
the mean in healthy nonsmokers, which did not contribute to the
overall ISAE score. Black circles represent values considered
abnormal, i.e., more than 2 standard deviations from the mean,
in the direction of the smoking-induced change, and which did
contribute to the ISAE. As an example of how the data were used to
calculate the ISAE, one healthy smoker is indicated by an arrow in
each of the 4 panels, representing how that individual expressed
the 4 genes chosen as examples. A. Expression of protein
phosphatase 1, regulatory (inhibitor) subunit 16B (PPP1R16B).
The healthy smoker marked with the arrow has abnormal
expression for this gene and received a ‘‘1’’ toward the ISAE. B.
Expression of chondroitin sulfate N-acetylgalactosaminyltransfer-
ase 1 (CSGALNACT1). The representative healthy smoker
(arrow) had normal expression for this gene and thus had a ‘‘0’’
toward the index for this gene. C. Expression of glutathione
peroxidase 2 (GPX2). The representative healthy smoker (arrow)
had abnormal expression for this gene and thus had a ‘‘1’’ toward
the index for this gene. D. Expression of cytochrome P450, family
1, subfamily A, polypeptide 1 (CYP1A1). The representative
individual (arrow) had normal expression for this gene and
received a ‘‘0’’ toward the index. Note that this healthy smoker
individual has normal expression within 2 standard deviations of
the mean in healthy nonsmokers for CSGALNACT1 and
CYP1A1, but abnormal expression for PPP1R16B and GPX2.
(TIFF)
Figure S2 Distribution of smoking exposure parame-
ters in low responder and high responder healthy
smokers. The abscissa displays the two groups. Each individual
is represented by a black diamond. A. Smoking history in pack-yr
is represented on the ordinate. There is no significant difference
between the two groups for pack-yr (p.0.1). B. Smoking duration
in years is represented on the ordinate. There is no significant
difference between the two groups for years of smoking (p.0.2).
(TIF)
Figure S3 Genome-wide gene expression in the small
airway epithelium of high responder and COPD smok-
ers vs. low responder healthy smokers. Differentially
expressed genes were evaluated in the primary set of subjects
(n=51 in the combined high responder/COPD group; n=29 low
responder healthy smokers) and the signature evaluated in the
independent validation set (n=9 low responder healthy smokers,
n=5 high responder healthy smokers, n=14 COPD smokers). A.
Cluster plot. Probe sets expressed above average are represented
in red, below average in blue, and average in white. Each row
represents one probe set, or gene, and each column represents an
individual subject. COPD smokers are represented by red, high
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22798responder healthy smokers by orange, and low responder healthy
smokers by yellow. B. Principal components analysis of gene
expression in COPD smoker, high responder and low responder
healthy smokers. Each axis represents one principal component
(PC), with PC1 on the x axis and PC2 on the y axis. Low
responder healthy smokers are represented by yellow dots, high
responder healthy smokers by orange dots and COPD smokers by
red dots.
(TIF)
Table S1 Identity of validation set subjects.
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Table S2 Smoking-related differentially expressed
genes in the small airway epithelium of healthy
nonsmokers and healthy smokers.
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Table S3 TaqMan confirmation of selected genes.
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Table S4 Overlap of genes differentially expressed in
the SAE of healthy smokers vs nonsmokers with other
reported smoking responsive genes.
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Table S5 Characteristics of the ISAE among the study
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Table S6 Demographics of low responder and high
responder healthy smokers.
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Table S7 Genes differentially expressed in the small
airway epithelium of high responder healthy smokers vs
low responder healthy smokers.
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Table S8 Genes differentially expressed in the small
airway epithelium of COPD smokers vs low responder
healthy smokers.
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Table S9 Genes differentially expressed in the small
airway epithelium of COPD smokers and high respond-
er smokers vs low responder smokers.
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